47 results about "Neuroregeneration" patented technology

The invention provides a nerve growth factor functionalized exosome as well as a preparation method and application thereof. The functionalized exosome can activate a Wnt / beta-catenin signal channel to maintain dryness of corneal limbal stem cells (LSCs) so as to promote corneal epithelium repair, can activate a cAMP signal channel to relieve inflammatory response and promote corneal nerve regeneration, and can be used for treating or relieving corneal chemical burns, including relieving inflammatory response, reducing stromal scar formation and inhibiting corneal neovascularization. Corneal epithelium repair and nerve regeneration are promoted.

The invention provides multifunctional bionic hydrogel as well as preparation and application thereof in traumatic brain injury treatment, and belongs to the field of biomedical materials. The preparation method comprises the following steps: combining polydopamine modified hemoglobin nanoparticles with curcumin-based carbon quantum dots with anti-inflammatory activity, and embedding into bionic hyaluronic acid-collagen double-network hydrogel, so as to prepare the multifunctional bionic hydrogel. The hydrogel can effectively relieve neuron hypoxia, reduce apoptosis, promote the polarity of microglial cells to be converted into anti-inflammatory phenotype, and significantly down-regulate the expression of S100A8, thereby inhibiting pathological neural immune crosstalk. In a traumatic brain injury model, hydrogel implantation improves the pathological microenvironment, enhances endogenous nerve regeneration, and ultimately results in significant neurological function and cognitive recovery. The multifunctional bionic hydrogel prepared by the invention has a good application prospect in preparation of materials for preventing and / or treating traumatic brain injury.

Therefore, this disclosure provides a genetically engineered mesenchymal stem cell (MSC) population, including an expression vector containing the Akt or HGF gene and the PD-L1 gene. It also provides a method for synergistically improving the survival status and immunomodulatory capacity of mesenchymal stem cells or enhancing their proliferation, including transfecting mesenchymal stem cells with the Akt or HGF gene and the PD-L1 gene; and a method for preventing, improving, and / or treating ischemic conditions, enhancing neurogenesis, or reducing neuronal death, including administering an effective amount of the genetically engineered mesenchymal stem cell population of this disclosure to individuals in need.

The present invention provides boron-containing isoquinoline compounds as protein kinase-modulating compounds. These compounds are useful as neuroprotective and neuro-regenerative agents for the amelioration of glaucoma and other ocular neuropathies.

The invention relates to a spinal cord injury repair method based on four-dimensional multifunctional hydrogel, which comprises the following steps: firstly, encapsulating NT-3 in PLGA (poly (lactic-co-glycolic acid)) microspheres through a microsphere technology, and integrating HCT (Hydroxycycline Computed Tomography) into SilMA hydrogel, so as to construct four-dimensional multifunctional hydrogel 4DMSH with time specificity; the hydrogel shows a remarkable anti-inflammatory effect in an in-vivo experiment, can effectively inhibit the inflammatory reaction at the early stage of spinal cord injury, promotes eNSCs to differentiate into neurons by improving a microenvironment and inhibits formation of glial scars, so that the nerve repair efficiency is improved; the four-dimensional multifunctional hydrogel has time specificity and can create an anti-inflammatory and neuroactive microenvironment, so that effective spinal cord injury repair and nerve regeneration are realized; the hydrogel can be widely applied to SCI treatment, and a brand new strategy is provided for repairing nervous system injury.

The present invention relates to a customizable injectable solution comprising Human Growth Hormone (HGH), Insulin-like Growth Factor 1 (IGF-1), or a growth hormone secretagogue such as sermorelin or ipamorelin, combined with a blend of nutrients including amino acids, vitamins, electrolytes, functional mushroom extracts, and optionally mushroom mycelium. The solution is delivered via a dual-chamber syringe to preserve component stability, with mixing occurring immediately before administration. The formulation is suitable for subcutaneous, intramuscular, or intravenous injection and may be tailored for muscle growth, cognitive performance, immune support, or neuroregeneration. The invention also contemplates injectable formulations of functional mushrooms alone, as well as alternative delivery methods such as sublingual troches containing GH-inducing peptides, functional mushrooms, and ketamine. This system provides a versatile, bioavailable, and clinically adaptable approach to personalized health optimization.

This invention discloses a neurotrophic brain protein peptide composition and its applications, belonging to the field of food technology. The components of the composition provided by this invention have synergistic effects. On the one hand, they reduce the damage of oxidative stress to the nervous system, improve sleep quality, and create a favorable environment for the repair and regeneration of the nervous system. On the other hand, they provide the raw materials needed for the maintenance, repair, and regeneration of nerve cells, as well as the synthesis of neurotransmitters, ensuring energy supply and the activity of the required enzyme systems, thereby achieving the effect of effectively nourishing / repairing nerves and / or promoting nerve regeneration. The provided composition does not use organic reagents, is environmentally friendly, and has high safety; it has low preparation cost and a good taste.

The present invention relates to a technique capable of treating a retinal neurodegenerative disease through regeneration of a retinal nerve by targeting Prox1 in the mammalian retina using an inhibitor which inhibits Prox1 expression or migration. According to the present invention, inducing the regeneration of the damaged retina in mammals, and thus can be commonly applied to the treatment of various retinal neurodegenerative diseases causing vision loss, and furthermore, when combining with a selective retinal nerve differentiation method or the like, it is expected that the method can be used for the development of an innovative retinal regeneration method capable of selectively regenerating only specific degenerating retinal neurons.

The present application relates to the technical field of biological medicine, and particularly relates to application of a nucleic acid vector encoding a macrophage monocarboxylate transporter MCT1 in preparation of a pharmaceutical composition for promoting corneal nerve regeneration and recovery of corneal sensitivity after corneal nerve injury. The present application finds that after corneal nerve injury, increasing the level of macrophage MCT1 can drive the change of the metabolic mode of macrophages to the direction of enhanced oxidative phosphorylation and reduced glycolysis, reduce the expression of local pro-inflammatory related factors, and increase the level of pro-regeneration factors and neurotrophic factors, thereby improving the regeneration of corneal nerve structure and the recovery of sensory function. Therefore, a macrophage-targeted or macrophage-biased expression vector containing a nucleic acid sequence encoding MCT1 can be used for preparation of a pharmaceutical composition for treating corneal nerve injury.

The application discloses a preparation method of a carboxylated silk fibroin hydrogel composite nerve conduit. The carboxylated silk fibroin is chemically crosslinked with chitosan amino groups, the crosslinking is carried out in an aqueous solution, and no organic solvent such as ethanol is contained, so that the cell activity is not inhibited, the safety hazard to the human body is avoided, and the temperature and pH do not need to be additionally controlled, which is beneficial to the stability of vascular endothelial growth factor, and the hydrogel can be formed in a very short time, and the VEGF with the function of blood vessel regeneration is rich in the application, so that the neuroangiogenesis is enhanced, and the nerve regeneration is promoted.

The invention discloses a composition for enhancing memory and improving cognitive function and application. The composition disclosed by the invention comprises acanthopanax, ginseng, Chinese wolfberry fruits, gastrodia elata, spina date seeds, poria cocos, Chinese yams, lotus seeds, gordon euryale seeds, mulberries, longan pulp, fresh ginger, walnut powder, egg protein powder, blueberry powder, raspberry powder, pumpkin seed powder, oat powder, spirulina powder, dark chocolate powder, a vitamin B group compound, gamma-aminobutyric acid, galactooligosaccharide and citric acid. According to the invention, a multi-channel and multi-target collaborative network is constructed by taking acanthopanax senticosus as a core, through multiple channels such as nerve regeneration, energy metabolism, oxidative stress, signal transduction, endocrine regulation and the like, different nodes such as neurons, neuroglial cells, cerebrovascular endothelium and the like are targeted, the overall optimization of the memory function is realized on the system level, and the memory function is optimized. The core idea of systematic biology of overall regulation and control is reflected, and the composition prepared from the composition has the effects of improving memory, learning ability and cognitive ability.

The invention discloses a magnetic control electric three-layer composite nerve scaffold for nerve regeneration microenvironment stage adaptation and a preparation method thereof. The outer layer of the stent is a PLLA-IAA membrane responding to inflammation microenvironment stimulation, the middle of the stent is an SPIONs-doped piezoelectric layer, and the inner layer of the stent is an Nrg-1-loaded neurotrophic factor sustained release layer. In the initial stage of stent implantation, reactive oxygen species (ROS) stimulates a responsive chain segment to break, and IAA is quickly released to inhibit an inflammatory microenvironment; then, an alternating magnetic field is applied to cause vibration of the SPIONs, formation of an electric signal in the piezoelectric layer is triggered, and a favorable electrophysiological microenvironment is provided for promoting neuronal differentiation and axon regeneration; under the action of environmental degradation, the spinning membrane structure disintegrates slowly and continuously releases the neurotrophic factor Nrg-1 so as to promote myelin sheath formation. The stent innovatively integrates the requirements of three stages of a nerve regeneration microenvironment, and realizes accurate, dynamic and multi-dimensional regulation and control of high-efficiency regeneration.

The application belongs to the field of biomedical science and neurology, and particularly relates to application of CHCHD2 gene and a protein coded by the CHCHD2 gene in preparation of a product for promoting proliferation and differentiation of neural stem cells. The application proves that the CHCHD2 gene and the protein coded by the CHCHD2 gene are highly expressed in in-vivo neural development and in-vitro neural differentiation process; and that knocking down or over-expressing the CHCHD2 gene or the protein coded by the CHCHD2 gene has a certain regulating effect on proliferation and differentiation of neural stem cells. The application provides a new scheme for preparation of a product for promoting proliferation and differentiation of neural stem cells, and provides a new target for drug research and development of neural regeneration and repair treatment of central nervous system development deficiency diseases, neurodegenerative diseases, cerebrovascular diseases, craniocerebral and spinal cord injuries.

The invention discloses a neuropeptide S for promoting mouse spinal cord injury repair by regulating and controlling endogenous NSPCs to differentiate into neurons and perform axonal regeneration, and belongs to the field of biological medicine and nerve repair. According to the technical scheme of the invention, a complete T11 spinal cord injury mouse model is transplanted and treated by adopting a thermo-sensitive hydrogel stent loaded with NPS. In-vitro experiments show that NPS can significantly promote neural stem / progenitor cells to differentiate into neurons and prolong axons. In-vivo experiments show that the immune response of an injured area is relieved, endogenous nerve stem / progenitor cells migrate and are differentiated into functional neurons, axons extend, more synapses are formed, and the movement function of hind limbs is obviously recovered. NPS activates downstream Ca < 2 + > and cAMP signal channels through an NPS-NPSR axis, and regulates and controls polygene expression, so that nerve regeneration and functional recovery are promoted. The NPS provided by the invention provides an efficient and feasible treatment strategy for spinal cord injury repair, and has an important clinical application prospect.

The invention relates to a particular modified camelid single chain antibody called VHHNPX and uses of VHHNPX in new methods for the efficient delivery of molecular cargos inside target cells (in particular neurons and eye retina cells). The invention further relates to a Neurovita short interfering peptide suitable for neuroprotection and neuroregeneration and uses thereof, in particular a Neurovita peptide short fragment encoding a PDZ-binding motif (PBM) inhibiting the PDZ domain of the human MAST2 & MAST1 enzymes. The invention also relates to polypeptides comprising this Neurovita short peptide, notably peptides further comprising a cell-penetrating molecule (CPM), and uses thereof.

The invention relates to a Neurovita peptide short fragment encoding a PDZ-binding motif (PBM) inhibiting the PDZ domain of the human MAST2 & MAST1 enzymes. The invention also relates to polypeptides comprising this Neurovita short peptide, notably peptides further comprising a cell-penetrating molecule (CPM), and uses thereof.

The present invention relates to a customizable injectable solution comprising Human Growth Hormone (HGH), Insulin-like Growth Factor 1 (IGF-1), or a growth hormone secretagogue such as sermorelin or ipamorelin, combined with a blend of nutrients including amino acids, vitamins, electrolytes, functional mushroom extracts, and optionally mushroom mycelium. The solution is delivered via a dual-chamber syringe to preserve component stability, with mixing occurring immediately before administration. The formulation is suitable for subcutaneous, intramuscular, or intravenous injection and may be tailored for muscle growth, cognitive performance, immune support, or neuroregeneration. The invention also contemplates injectable formulations of functional mushrooms alone, as well as alternative delivery methods such as sublingual troches containing GH-inducing peptides, functional mushrooms, and ketamine. This system provides a versatile, bioavailable, and clinically adaptable approach to personalized health optimization.

The invention discloses an application of a connective tissue growth factor in preparation of a drug for promoting neuronal growth. The invention proposes and verifies that the connective tissue growth factor can promote the growth of neurons, realize effective regeneration of a nervous system and accelerate the recovery of sensory and motor functions for the first time; the adeno-associated virus expressing the connective tissue growth factor also has the same neuron growth promotion and nervous system regeneration effects, and can be widely applied to clinical treatment of related diseases with nerve regeneration requirements.

Systems, devices and methods are disclosed for the treatment of injured peripheral nerves or other tissue using electrical stimulation. The systems can be used either in intraoperative or peri-operative settings and incorporate the use of either a plurality of monopolar electrodes with a patch used as return or a plurality of bipolar electrodes such as a cuff. The systems can provide hands-free delivery of electrical stimulation therapy over a predetermined set of time.

This invention discloses a sustained-release membrane for postoperative treatment of diabetic peripheral neuropathy and its preparation method. The sustained-release membrane comprises, from the outside in, a PLGA nanofiber outer layer containing tacrolimus and magnesium hydroxide nanoparticles, a glucose-responsive hydrogel middle layer containing insulin and glucose oxidase / catalase, and a PCL-oriented nanofiber inner layer containing methylcobalamin. The layers are connected by a polydopamine interface layer, and the outermost surface of the outer layer is coated with a hyaluronic acid anti-adhesion coating. Insulin, as a local neurotrophic factor, directly activates the PI3K / Akt / mTOR and ERK / MAPK signaling pathways, promoting axonal regeneration and myelin repair. The sustained-release membrane integrates three major functions: immunomodulation / anti-inflammation, glucose-responsive insulin neurotrophic delivery, and sustained nerve regeneration promotion. It prevents postoperative nerve re-adhesion through a spatiotemporal sequential drug release strategy. All components are biodegradable and do not require secondary surgery for removal.

The invention relates to a vector containing a Plaur gene and application of the vector in nerve injury related diseases. The invention proves that the AAV virus vector is used for enhancing the expression of the Plaur gene, so that the neuronal axon regeneration capacity can be obviously enhanced, and the nerve regeneration efficiency is improved. The effect is verified in an optic nerve injury model. According to the application, a new target is provided for nerve protection and nerve regeneration, a gene therapy means is provided for nerve regeneration, and a new way is opened up for treatment of nerve injury related diseases.

The present disclosure describes the use of immune modulators to promote nerve growth and regeneration, particularly in the context of nerve deficit stemming from trauma and disease. In particular, the disclosure provides for the use of CXCR4 antagonists, STAT3 activators, and an agent that increases levels of nitric oxide, either alone or in any combination of these drugs, in surgery performed to treat nerve deficit conditions, especially peripheral nerve deficit conditions caused by cut injury or tear injury, the method especially useful in bridging nerve gaps of 3 cm or longer.

This invention relates to the field of medical materials technology, specifically to an MXene-based artificial dura mater, its preparation method, and its applications. The MXene-based artificial dura mater has a layered structure, comprising an upper membrane and a lower membrane. The upper membrane is composed of amino-modified MXene; the lower membrane uses chitosan / gelatin hydrogel as a matrix, doped with polydopamine-coated MXene. The upper and lower membranes are bonded together by chemical bonds formed by the reaction of amino groups in the upper and lower membranes with a crosslinking agent. The MXene-based artificial dura mater not only achieves the sealing and barrier functions of traditional dura mater repair but also possesses the ability to regulate the injury microenvironment and promote nerve regeneration. Through its unique layered structural design, it can simultaneously regulate inflammatory responses and promote endogenous nerve regeneration during dura mater repair, providing more comprehensive support for the functional recovery of the central nervous system.

The invention provides application of ultrafine nanoparticles derived from human umbilical cord mesenchymal stem cells in preparation of a medicine for preventing and / or treating diseases caused by nerve cell injury, and belongs to the technical field of biological medicines. The invention provides an application of human umbilical cord mesenchymal stem cell (ucMSC-supermers) in preparation of a medicine for preventing and / or treating diseases caused by nerve cell injury, and particularly provides an application of the human umbilical cord mesenchymal stem cell (ucMSC-supermers) in preparation of the medicine for preventing and / or treating the diseases caused by the nerve cell injury. As novel non-membranous extracellular nanoparticles, the mesenchymal stem cell-derived ultramicro nanoparticles are small in particle size, are not wrapped by a membranous structure, have stronger tissue penetrating power and higher cellular uptake efficiency, enrich bioactive substances with higher abundance, can efficiently promote axonal regeneration, and can be used for preparing a novel non-membranous extracellular nanoparticle. The effect of promoting nerve regeneration and repair is obviously better than that of the HucMSC-sEV under the same condition, and the treatment effect on traumatic diseases of the central nervous system is effectively improved.

The invention provides a nerve conduit for nerve injury repair and a preparation method thereof, and belongs to the technical field of medical materials. The nerve conduit provided by the invention is composed of three-dimensional conductive composite hydrogel loaded with human endometrial mesenchymal stem cells, and conductive polymer polypyrrole is grafted and crosslinked in a natural biological material network formed by chitosan and gelatin. The catheter has good biocompatibility, degradability and stable conductivity, can simulate an electrophysiological microenvironment for nerve regeneration, and can generate synergy with a paracrine function of stem cells, so that the directional regeneration of axons is effectively guided, and the formation of myelin sheaths is promoted. In-vivo and in-vitro experiments show that when the catheter is used for repairing peripheral nerve long segment defects, the function recovery effect of the catheter is equivalent to that of autologous nerve transplantation, and an ideal alternative scheme is provided for clinic.

The invention belongs to the field of biological medicine, and provides a brain nerve repairing and regenerating composition as well as a preparation method and application thereof. The composition consists of 28 amino acids, mannitol low-molecular peptide and endogenous coenzyme B12, and all the components have a synergistic effect: the amino acids supply energy, regulate the environment in the brain, resist oxidation and regulate emotion; mannitol low-molecular peptide has nerve protection, growth promotion, oxidation resistance and inflammation resistance; the endogenous coenzyme B12 promotes nerve regeneration, promotes myeloid phospholipid formation, prevents encephalatrophy and improves mental symptoms. The preparation method comprises the following steps: accurately weighing the raw materials, uniformly mixing at proper temperature and humidity, sterilizing and packaging. The composition can remove neuroendotoxin, promote synthesis of nucleic acid and protein into nerve cells, further improve brain functions, repair cranial nerves and activate brain cells, and is suitable for treatment of multiple nervous system diseases such as insomnia, neuralgia, neuromuscular diseases, epilepsy, migraine and mental and psychological disorders.

Systems, devices and methods are disclosed related to shapeable lead assemblies. Such lead assemblies can be configured to be shaped in a desired manner before and / or during a procedure, such as, for example, after the lead assembly has been at least partially placed within the anatomy of a subject. The shapeable lead assembly can be shaped during a neuroregenerative procedure to contact and / or otherwise interface with a targeted nerve.

The present subject matter relates to techniques for treating a neurodegenerative disease. The disclosed system can include a transducer for stimulating a target tissue with focused ultrasound (FUS) and at least one nanocup. The transducer induces the FUS with a predetermined parameter to open the target tissue. The nanocup can include at least one gas pocket within a cavity of the nanocup and an effective amount of an active agent for neuroregeneration.

The present invention relates to a specific lipid emulsion comprising ≥ 5 % stearidonic acid and ≥ 15 % α-linolenic acid for use in neuroprotection, neuroregeneration and neurodevelopment.

The invention belongs to the technical field of bioengineering, and particularly relates to an A2aR-His6-G alpha 16-HEK cell strain capable of stably expressing a human adenosine A2a receptor (A2aR). According to the invention, the Galpha16 protein and the A2aR which are determined by screening are sequentially expressed in HEK-FlpIn cells, and the A2aR-His6-Galpha16-HEK cell strain capable of stably expressing the human A2aR is obtained by screening; a cell evaluation model suitable for calcium signal detection is constructed, and the cell evaluation model can be used for screening and detecting A2aR-targeting agonists and antagonists; the kit has the characteristics of more reliable detection result, higher sensitivity, larger screening flux, short experimental period, simplicity and convenience in operation and the like, can greatly improve the screening and evaluation efficiency of A2aR-targeting agonists and antagonists, and meanwhile, has a significant meaning for A2aR-related diseases. Candidate drug molecules are provided for treatment of diseases such as motion control, neurodegenerative diseases, tumor immunoregulation, anti-depression effect, heart diseases, nerve regeneration and immunoregulation, the problem that at present, A2aR target-based drug screening does not have a high-throughput detection method based on calcium signal detection is solved, and the method has obvious practical application value.